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ABSTRACT
The discovery of missense mutations of ALK gene identified this receptor tyrosine 
kinase as a therapeutic target in neuroblastoma (NB). Moreover, a high level of ALK 
protein has been associated with metastatic NB cases and with a worse prognosis, 
suggesting that also ALK overexpression is involved in NB tumorigenesis. Since 
miRNAs play key roles in the regulation of gene expression we aimed at identifying 
those miRNAs that can regulate ALK in NB. We therefore analyzed the genome-wide 
expression profile of miRNAs in two sample sets of 16 NB cell lines and 22 NB samples 
by using miRNA microarrays. Both sample sets were then divided into two subgroups 
showing high (ALK+) or low/absent (ALK-) expression of ALK. Results showed a 
down-regulation of 30 and 23 miRNAs (p-value <0.05) in the ALK+ group in NB cell 
lines and samples, respectively. Validation analysis indicated that miR-424-5p and 
miR-503-5p, belonging to the same cluster, were differentially expressed in both NB 
cell lines and tumor samples. Although only miR-424-5p showed a direct binding to 
ALK 3’-UTR, both miRNAs led to a remarkable decreasing of ALK protein as well as to 
the inhibition of cell viability in ALK+ NB cell lines. In conclusion, our data indicate 
that both miR-424-5p and miR-503-5p are involved in regulating ALK expression in 
NB, either by directly targeting ALK receptor or indirectly, and may thus serve as 
potential therapeutic tools in ALK dependent NBs.
INTRODUCTION
Neuroblastoma (NB) is a neural crest-derived 
pediatric cancer that shows a peculiar heterogeneity 
in its clinical presentation and outcome as well as in 
the molecular mechanisms that underlie its genetic 
predisposition and aggressiveness [1, 2]. Over the years 
many studies have contributed to shed light on several 
non-random somatic alterations that characterize NB 
[1], including MYCN proto-oncogene amplification, 
which is associated with aggressive clinical disease 
[3–5].
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The Anaplastic Lymphoma Kinase (ALK) is a trans-
membrane receptor tyrosine kinase (RTK), belonging to 
the insulin receptor superfamily of RTKs. The expression 
of ALK is restricted to the developing nervous system 
and is supposed to play a role in the regulation of 
neuronal differentiation [6]. ALK catalytic domain was 
originally identified in the t(2;5)(p23;q35) chromosomal 
translocation that produces the oncogenic fusion of the 
amino terminus of nucleophosmin (NPM) to the catalytic 
intracellular domain of ALK [7]. This rearrangement 
occurs in most of the Anaplastic Large Cell Lymphomas 
(ALCL), which mainly affect children and young adults 
[7]. Since then, ALK has been found to be involved in 
several other cancers, mainly as a consequence of different 
chromosomal translocations such as those reported in 
inflammatory myofibroblastic tumors [8], non-small cell 
lung cancer [9] and diffuse large B-cell lymphomas [10]. 
In 2008 ALK emerged also as a major predisposition gene 
in NB, paving the way for new target-based therapeutical 
approaches for this tumor [11–14]. Indeed, several studies 
led to the identification of both germline and somatically 
acquired activating missense point mutations affecting 
the tyrosine kinase domain of ALK in about half of the 
families with recurrence of NB and 8-10% of sporadic 
NB cases [11–14], although this percentage increases 
significantly in the relapsed patient population [15, 16]. 
Among more than 20 different ALK mutations discovered 
so far, F1174, R1275 and F1245 are the three most 
frequent mutated codons, accounting for about 87% of all 
mutations affecting this RTK. They have been classified 
as gain-of-function mutations and demonstrated to have 
transforming capacities [17]. Moreover, about 4% of high-
risk NB patients show amplification of the ALK genomic 
locus, as well [18]. Therefore, great efforts are now aimed 
at pharmacologically inhibiting ALK activity in NB cells 
by taking advantage of small molecule inhibitors such 
as crizotinib, an FDA-approved anticancer drug that 
exhibited efficacy in non-small cell lung cancers harboring 
ALK translocations [19]. Conversely, crizotinib showed 
limited activity in NB patients with ALK-activating 
mutations [20] that revealed differential sensitivity to ALK 
inhibitors in both preclinical and clinical studies [18, 21].
ALK expression in NB was first described by Lamant 
and colleagues [22] and more recently we and others 
reported that wild type ALK is frequently overexpressed 
in metastatic NB and that, similarly to activating ALK 
mutations, its overexpression is correlated with poor 
clinical outcome [23, 24]. Hence, it has been suggested 
that in addition to activating mutations also an aberrant 
level of wild type ALK expression could be involved in NB 
oncogenesis and progression, although it probably should 
reach a critical threshold for triggering ALK activation [23]. 
Indeed, primary NBs with ALK mutations were reported to 
invariably exhibit high levels of ALK expression [24], and 
NBs with an expression of wild type ALK comparable to 
that of ALK mutated tumors showed a similar poor outcome 
[24]. Notably, wild type ALK expression in the neural crest 
progenitor cells JoMa1 can drive the formation of malignant 
tumors in nude mice [25]. Altogether, these results suggested 
that the inhibition of either mutated or wild type ALK 
expression may exert beneficial effects in NB patients.
Protein expression can be regulated by microRNAs 
(miRNAs), which are short, single-stranded RNA molecules 
[26], and constitute a family of highly conserved non-coding 
small RNAs. Indeed, miRNAs down-regulate the expression 
of specific proteins at the post-transcriptional level, mainly 
by targeting the 3′-untranslated region (3′-UTR) of their 
target mRNAs. Therefore, miRNAs play key roles in various 
cellular processes in both animals and human diseases [26]. 
In human cancers, miRNAs can function as oncogenes or 
tumor suppressors and their expression profile may correlate 
to prognosis, diagnosis and response to treatment [27]. The 
role of miRNAs in human cancers was initially demonstrated 
in chronic lymphocytic leukemia, where a loss of miR-15a 
and miR-16-1 due to the 13q14 deletion was found in over 
half of cases [28]. Since then, the deregulation of miRNAs 
expression has been demonstrated in other types of cancers, 
including NB [29–34]. Although a large number of miRNAs 
have been identified to date, the role of the vast majority of 
them in tumorigenesis remains to be determined. This work 
is aimed at identifying those miRNAs that can specifically 
regulate ALK protein levels. Indeed, in our view the design 
of novel therapeutic strategies that lead to the modulation of 
miRNAs activity, and consequently to the inhibition of ALK 
expression in NB, might constitute a novel approach for the 
treatment of NB.
RESULTS
Determination of ALK+ and ALK- subgroups in 
NB cell lines
To identify miRNAs differentially expressed 
between ALK+ and ALK- NB cell lines we carried 
out analyses in a set of NB cell lines to determine both 
mRNA and protein ALK expression. We thus identified 
two subgroups of cell lines showing either high ALK 
expression (ALK+) or low/absent ALK expression (ALK-) 
(Figure 1). The expression of ALK protein was detected in 
10 out of 16 NB cell lines (Supplementary Figure 1B) that 
were thus considered as belonging to the ALK+ subgroup. 
Although SKNBE2C cell line showed a low amount of 
ALK mRNA (Supplementary Figure 1A), we could not 
detect any protein expression (Supplementary Figure 1B). 
Therefore, we considered SKNBE2C as belonging to the 
ALK- subgroup, which consisted of 6 NB cell lines.
Determination of ALK+ and ALK- subgroups in 
NB tumor samples
Similarly, to identify miRNAs differentially 
expressed between ALK+ and ALK- NB tumors we 
first analyzed ALK mRNA expression in a set of tumor 
samples to determine subgroups of NBs expressing 
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low or high levels of ALK. Since the amount of frozen 
tumor tissue was insufficient to perform protein analysis, 
we grouped NB tumor samples on the basis of their 
different ALK mRNA expression levels, thus identifying 
an ALK+ and an ALK- subgroup, each consisting of 11 
samples (Figure 1, Supplementary Figure 2). These 22 
NB tumor samples were derived from a selection of 
120 frozen NB specimens that were randomly chosen 
from our NB tissue bank, and considered eligible for 
RNA extraction only if tumor cell content reached 
70%. After quality control and determination of 
RNA concentrations, 75 samples resulted suitable for 
subsequent analyses. Moreover, in order to rule out 
a possible bias in both miRNAs and ALK expression 
we excluded 17 samples that showed either MYCN 
amplification or high MYCN expression (Supplementary 
Figure 3A), although high levels of MYCN mRNA did 
not significantly influence those of ALK in our sample 
set (Supplementary Figure 4). Last, from the remaining 
58 MYCN single copy NB samples we defined the two 
ALK+ and ALK- subgroups. To maximize the difference 
in ALK expression between the two subgroups, we 
selected the 11 samples that showed the highest and the 
lowest expression of ALK (Figure 1). MYCN mRNA 
expression in both subgroups was evenly distributed 
(Supplementary Figure 3B).
Identification of differentially expressed 
miRNAs in ALK+ and ALK- NB cell lines 
and tumor samples
MiRNAs expression analysis was carried out 
in 16 NB cell lines and 22 tumor samples by using 
Human microRNA Microarray (Agilent Technologies), 
consisting in a set of probes for 866 human miRNAs. 
After filtering, condensing by replicates average and 
controlling spots removal, the quantitative analysis 
provided an expression dataset composed by 388 
and 675 miRNAs in NB cell lines and NB samples, 
respectively. We identified two relevant sets of 71 and 43 
miRNAs, which were differentially expressed in ALK+ 
and ALK- subgroups in NB cell lines and NB samples, 
respectively (raw p-values < 0.05), and then made a 
hierarchical clustering to detect similarity relationships 
in miRNAs log2-transformed expressions (Figure 2, 
Figure 3). Overall, 30/71 miRNAs in NB cell lines and 
23/43 in NB samples were down-regulated in the ALK+ 
subgroup. Interestingly, three miRNAs (miR-424-5p, 
Figure 1: ALK expression in NB cell lines and samples. ALK mRNA expression was performed by qPCR and data from NB cell 
lines and tumor samples were box-plotted (beeswarm box plot) using BoxPlotR, a web-tool for generation of box plots publicly available 
at http://boxplot.tyerslab.com. Numbers in the Y-axis represents the fold change in expression with respect to the less expressed sample, 
which was set as 1. Histograms reporting expression results for each sample from NB cell lines and tumors are shown in Supplementary 
Figures 1 and 2, respectively. p-value < 0.05 (*); p-value < 0.01 (**).
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miR-520e, and miR-526b-3p) emerged as candidates 
from both analyses (Figure 4A). We then considered 
for validation analysis by qPCR 12/30 miRNAs from 
cell lines (Table 1) and 6/23 from tumor samples (Table 
2) for a total number of 15 miRNAs, as three were 
included in both sample sets. The other 12 candidate 
miRNAs were selected if they matched one or more of 
the following criteria: i) in silico prediction of potential 
ALK 3’-UTR targeting; ii) fold change in miRNAs 
expression > 2; iii) supporting data from literature for an 
involvement of the candidate miRNA with either ALK, 
NB or cancer in general.
Validation of candidate miRNAs by qPCR
Validation analysis of the 15 candidate miRNAs was 
performed by qPCR on both sets of samples employed for 
miRNAs expression screening, which included 16 NB 
cell lines and 22 NB tumor samples. Of the three miRNAs 
identified by both genome-wide screenings only miR-
424-5p was validated in both NB cell lines and tumor 
samples (Figure 4B). Conversely, miR-21-5p, miR-22-3p, 
miR-23a-3p, miR-29a-3p, miR-29b-3p, miR-29b-1-5p, 
miR-100-5p and miR-221-3p were validated in NB cell 
lines only (i.e. the sample set from which they emerged as 
Figure 2: Hierarchical clustering of differentially expressed miRNAs in NB cell lines. Differential expression analysis 
between ALK+ and ALK- categories was carried out using Student's t-test (unpaired, two-tailed, unequal variance). SKNBE2 cell line 
was removed from the analysis for low quality hybridization. 71 miRNAs showed raw p-value < 0.05. miR-424-5p and miR-503-5p are 
highlighted with a red font.
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candidates) (Supplementary Figure 5), whereas let-7g-5p 
and miR-451a were validated in tumor samples only (i.e. 
the sample set from which they emerged as candidates) 
(Supplementary Figure 6). Notably, miR-503-5p, which is 
a member of the same cluster that includes miR-424-5p, 
was also found to be differentially expressed in both sets 
of specimens (Supplementary Figures 5, 6).
Luciferase assay indicates a direct binding of 
miR-424-5p to ALK 3’-UTR
Target prediction program MiRanda (www.
microRNA.org) predicted a potential miRNA binding site 
at ALK 3’-UTR for miR-424-5p (Figure 4C). In order to 
assess whether miR-424-5p as well as miR-503-5p could 
regulate luciferase expression, we cloned the whole 450 bp 
of ALK 3’-UTR in the pMIR-REPORT vector, containing 
a transcriptional unit encoding firefly luciferase. The 
luciferase reporter vector and the renilla control vector 
were then transfected in a NB ALK negative cell line, 
namely SKNAS, together with miR synthetic mimics or 
a control siRNA. As a matter of fact, after normalization 
to renilla, the transfection of miR-424-5p mimic led to a 
reduction of about 24% and 16% of the relative luciferase 
activity after 48 and 72 hours, respectively, as resulting 
from a set of three independent experiments (Figure 5). 
Conversely, miR-503-5p transfections did not exhibit any 
reduction of luciferase activity (Figure 5).
Both miR-424-5p and miR-503-5p down-regulate 
ALK protein expression and limit cell viability in 
ALK+ NB cell lines
In order to demonstrate if miR-424-5p and miR-
503-5p might indeed regulate ALK expression, we 
analyzed two ALK+ NB cell lines (i.e. NB1 and SKNSH) 
by western blot after transiently transfecting them with 
either miR-424-5p or miR-503-5p mimics. Although we 
did not observe a direct binding of miR-503-5p to ALK 
3’-UTR, results showed that both miRNA mimics led 
Figure 3: Hierarchical clustering of differentially expressed miRNAs in NB tumor samples. Differential expression analysis 
between ALK+ and ALK- categories was carried out using Student's t-test (unpaired, two-tailed, unequal variance). Samples 2731 and 2347 
were removed from the analysis for low quality hybridization. 43 miRNAs showed raw p-value < 0.05. miR-424-5p is highlighted with a 
red font.
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to a remarkable reduction of ALK protein at 48 and 72 
hours post transfection in NB1 and SKNSH cell lines, 
respectively (Figure 6A), indicating that ALK expression 
can be regulated by both miRNAs. We next performed 
MTT analysis after miR-424-5p mimic transfection, which 
revealed a reduction of cell viability in NB1 cells at 48 and 
72 hours and in SKNSH cells at 72 hours. No significant 
impairment of cell number was observed in the ALK- cell 
line SKNAS (Figure 6B). Similarly, transfection of miR-
503-5p led to a significant reduction of cell viability in 
both NB1 and SKNSH cells at 48 and 72 hours, but also 
in SKNAS (Figure 6B). Finally, to better investigate the 
reduction of cell number observed by MTT, we performed 
cell cycle analysis in ALK+ and ALK- cell lines. Both 
miR-424-5p and miR-503-5p induced a G1 accumulation 
in ALK+ NB1 cells but not in SKNSH, although we 
observed an accumulation of the G1 phase also in SKNAS 
cells (Supplementary Figure 7).
DISCUSSION
Since ALK turned up as a key oncogene involved in 
the tumorigenesis of at least a subset of NB patients, great 
efforts have been made to develop an efficient system for 
its targeting, mainly by taking advantage of small molecule 
inhibitors, such as crizotinib. ALK missense mutations in 
general, and ALK F1174L in particular, however, proved 
to confer a relative resistance to this drug as a consequence 
of an increased ATP-binding affinity of the mutant, an 
effect that could be surmountable using higher doses 
of crizotinib or inhibitors with a higher affinity for the 
protein [35]. To overcome these difficulties, combinational 
treatments acting simultaneously on multiple targets as for 
instance that using PI3K/AKT/mTOR pathway inhibitors 
combined with crizotinib, have been investigated [36]. 
In addition, a second generation of ALK inhibitors [37–
39] or a combined targeting of an ALK inhibitor with 
liposomal siRNAs [40] have been proposed as better 
treatment options if compared with crizotinib alone. Aside 
from activating point mutations, we previously indicated 
that ALK expression is significantly up-regulated in 
metastatic NB, suggesting that its overexpression might 
contribute to the transformation of neuroblastic cells [23, 
24]. Here, we aimed to provide novel insights into the 
molecular mechanisms that control ALK expression in NB 
by searching for ALK regulatory miRNAs, thus providing 
Figure 4: Validation of candidate miRNAs. (A) Venn diagram representing the number of miRNAs that were found to be down-
regulated in ALK+ group (or up-regulated in ALK- group). Filtering criteria for prioritizing miRNAs for validation and functional analyses 
are described in the results. (B) Validation analysis of miRNAs expression was performed by qPCR and data were box-plotted using 
BoxPlotR. p-value < 0.05 (*); p-value < 0.01 (**). (C) miR-424-5p/ALK 3’-UTR alignment as predicted by MicroRNA.org. Sequence starts 
at 321 bp of ALK 3’-UTR. mirSVR score:-0.9220; PhastCons score: 0.5638.
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novel tools that might be exploited for inhibition of this 
membrane receptor.
We set out to determine a list of differentially 
expressed miRNAs that can distinguish between two 
groups of NBs, showing either high or low/absent 
expression of ALK, by a genome-wide approach. In the 
ALK+ subgroup our analysis identified two relevant sets 
of 30 and 23 down-regulated miRNAs in NB cell lines 
and samples, respectively. Among these, miR-424-5p 
emerged as a promising candidate from both miRNA 
expression profile analyses. Functional studies on a 
luciferase reporter vector bearing an ALK 3’-UTR insert 
demonstrated that miR-424-5p can, indeed, bind to ALK 
3’-UTR. Consistently with this observation, we assessed a 
remarkable down-regulation of endogenous ALK protein 
after transient transfection of miR-424-5p in two ALK 
expressing NB cell lines (SKNSH and NB1). In addition, 
miR-424-5p mediated down-regulation of ALK also led 
to a statistically significant decrease of cell viability, as 
assessed by MTT test in these two cell lines, although 
we cannot exclude that this effect might be due also to 
other miR-424-5p targets. Validation analysis of candidate 
miRNAs suggested also miR-503-5p as being significantly 
deregulated between ALK+ and ALK- NB cell line and 
tumor subgroups. Interestingly, miR-503-5p is clustered 
with miR-424-5p. Although we could not demonstrate 
a direct interaction with ALK 3’-UTR for miR-503-5p, 
we observed a similar result to that obtained with miR-
424-5p in its capability to down-regulate ALK protein as 
well as limit NB cells viability. However, miR-503-5p 
induced cell viability impairment also in an ALK- cell 
line, namely SKNAS, suggesting that this miRNA can 
Table 1: Candidate miRNAs from microarray analysis of NB cell lines 
miRNA ALK- group ALK+ group rawp-value Fold change
hsa-miR-526b-3p 1.92 0.27 0.042 3.14
hsa-miR-424-5p 8.02 6.72 0.008 2.48
hsa-miR-520e 2.86 2.13 0.032 1.65
hsa-miR-100-5p 7.87 3.59 0.019 19.45
hsa-miR-29b-3p 8.17 4.12 0.04 16.65
hsa-miR-29a-3p 9.48 5.46 0.009 16.20
hsa-miR-503-5p 5.68 2.95 0.022 6.65
hsa-miR-221-3p 5.56 2.88 0.015 6.41
hsa-miR-21-5p 11.31 8.73 0.002 5.98
hsa-miR-22-3p 7.82 5.60 0.007 4.67
hsa-miR-29b-1-5p 4.13 2.64 0.014 2.81
hsa-miR-23a-3p 7.93 6.68 0.016 2.37
The table reports data only for miRNAs selected for validation analysis. Expression values reported in the ALK+ and ALK- 
columns were log2-transformed and normalized.
Table 2: Candidate miRNAs from microarray analysis of NB tumor samples 
miRNA ALK- group ALK+ group rawp-value Fold change
hsa-miR-424-5p 6.54 4.72 0.017 3.51
hsa-miR-526b-3p 3.24 2.55 0.037 1.62
hsa-miR-520e 3.56 2.97 0.01 1.49
hsa-miR-451a 14.75 11.74 0.011 8.08
hsa-let-7g-5p 11.86 10.41 0.036 2.74
hsa-let-7i-5p 11.69 10.30 0.042 2.62
The table reports data only for miRNAs selected for validation analysis. Expression values reported in the ALK+ and ALK- 
columns were log2-transformed and normalized.
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Figure 5: ALK 3’-UTR luciferase assay. Firefly and Renilla luciferase activities were assessed 48 and 72 hours after transfection 
with miR-424-5p and miR-503-5p mimics in SKNAS cells. Firefly luciferase was firstly normalized to Renilla luciferase activity, and then 
normalized to the luciferase activity ratio observed in the empty vector. Negative Control siRNA values were set as 100%. p-value < 0.05 
(*); p-value < 0.01 (**).
Figure 6: Impairment of ALK expression and cell viability assay. (A) Western blot analysis of ALK after transient transfection 
with miR-424-5p and miR-503-5p mimics. SKNSH cells revealed a marked decreasing of ALK after 72 hours. NB1 cells showed a similar 
ALK reduction after 48 hours, although its expression restored at 72 hours (data not shown). Quantification of bands was performed by 
ImageJ software and experiments were repeated at least once with consistent results. (B) MTT test to assess cell viability after transient 
transfection with miR-424-5p and miR-503-5p mimics at 48 and 72 hours in two ALK+ cell lines (SKNSH and NB1) and one ALK- cell 
line (SKNAS). p-value < 0.05 (*); p-value < 0.01 (**).
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act through several different targets. Considering that 
clustered miRNAs may co-operatively act to regulate a 
same pathway or biological process, our observations 
suggest that miR-503-5p could also participate to regulate 
ALK expression, although indirectly. Both miR-424-5p 
and miR-503-5p have been shown previously to induce 
G1 cell cycle arrest in acute myeloid leukemia (AML) 
cell lines [41]. Cell cycle DNA profile in NB cell lines 
indicated that both miRNAs can induce a G1 accumulation 
only in ALK+ NB1 cells, but not in the other ALK+ 
cell line (SKNSH). Particularly, miR-503-5p exerted a 
broader effect on G1 accumulation in NB1. However, we 
observed that both miR-424-5p and miR-503-5p induced 
an accumulation of the G1 phase also in an ALK- cell line 
(SKNAS), indicating that in this cell line the effect should 
be mediated by target(s) of these two miRNAs other than 
ALK (Supplementary Figure 7). Indeed, both miR-424-
5p and miR-503-5p, as well as miRNAs in general, have 
hundreds of targets, including cell cycle regulators [41], 
and the effects on cell viability, cell death or cell cycle 
distribution may be mediated by several of their target 
transcripts.
MiR-424, namely miR-322 in rodents, maps on 
human chromosome Xq26.3. Together with miR-503 it 
is co-transcribed as a polycistronic primary transcript and 
thus belongs to a large cluster that comprises the miR-
424(322)-503 gene cluster [41–43]. Several studies have 
recently reported an important role played by miR-424 
and miR-503 in human malignancies. Indeed, miR-424 
controls important biological processes often perturbed 
in cancer such as cell-cycle progression, angiogenesis, 
cell differentiation and proliferation [44–46]. In this 
context it has been shown that miR-424 and miR-
503 may potentially act as tumor suppressors [47–51] 
and that are down-regulated in several human tumors, 
including hepatocellular carcinoma [52, 53], cervical 
cancer [54], acute myeloid leukemia [55], ovarian cancer 
[56], colon cancer [57], lung cancer [58], renal cancer 
[59], osteosarcoma [60], and bladder cancer [61] where 
miR-424 has a role in tumor invasion and epithelial-
mesenchymal transition. Conversely, other studies 
reported the up-regulation of miR-424 in pancreatic 
cancer, suggesting that in a specific context it may also 
act as a tumor promoter [62]. Moreover, overexpression 
of miR-424 has been shown to suppress proliferation 
and induce apoptosis of chronic myeloid leukemia cells 
carrying the Philadelphia chromosome, sensitizing these 
cells to Imatinib treatment [63]. Therefore, miR-424 has 
been proposed as a tumor suppressor acting via down-
regulation of BCR-ABL and its up-regulation may have 
a therapeutic effect in chronic myeloid leukemia [63]. 
Aberrant expression of miR-424-5p is also involved 
in resistance to anoikis and in epithelial-mesenchymal 
transition during the metastatic process of hepatocellular 
carcinoma, and its down-regulation significantly 
contributes to liver cancer progression [64]. Notably, both 
miR-424-5p and miR-503-5p came out as down-regulated 
miRNAs between ALK+ and ALK- ALCLs, since they 
were included in a signature of 56 miRNAs distinguishing 
ALK+ ALCL, ALK- ALCL and T-cells [65]. In addition 
to the wide literature underlining the important role of 
miR-424-5p and miR-503-5p in tumorigenesis, our results 
indicate now that the deregulation of these two miRNAs 
is also involved in controlling ALK expression in NB. 
To our knowledge this is the first genome-wide miRNA 
profiling that is aimed at identifying ALK regulator 
miRNAs. Notwithstanding that, a previous study based 
on in silico predictions identified miR-96 (i.e. miR-96-5p 
according to the last miRNA nomenclature conventions) 
to potentially bind to the ALK 3’-UTR and provided 
evidence that decreases in miR-96 could represent a 
mechanism underlying the aberrant expression of ALK in 
cancer cells [66].
In general, deregulation of miRNAs expression 
contributes to the pathogenesis of most, if not all, human 
neoplasias and malignant cells show dependence on the 
expression of miRNAs, so that small RNAs provide 
important opportunities for the development of novel 
miRNA-based therapies [67]. Indeed, miRNAs are 
considered potential diagnostic and therapeutic tools and 
the use of miRNA mimics or antagomirs is considered a 
promising strategy to correct gene regulatory networks 
and reverse the phenotype of cancer cells. The observation 
of a relative resistance to ALK inhibitors addresses the 
significance of discovering novel tools to impair ALK 
activity in NB. Our results indicate now a contributing 
role of miR-424-5p and miR-503-5p in controlling ALK 
expression and, thus, these two miRNAs may serve as 
novel therapeutic tools for those NBs that depend on ALK 
activation.
MATERIALS AND METHODS
NB cell lines and samples
The following 16 NB cell lines were employed 
in the genome-wide screening: ACN, GICAN, GILIN, 
GIMEN, LA1-5S, LAN1, LAN5, IMR32, IMR5, KELLY, 
SH-SY5Y, SKNAS, SKNBE(2), SKNBE2C, SKNSH, 
UKF-NB3. NB1 is an ALK amplified cell line and was 
used in functional experiments only. Name, origin and 
MYCN status of all NB cell lines used in this study are 
listed in Supplementary Table 1. Cell lines were cultured 
at 37°C and 5% CO2 and maintained in RPMI 1640, 
supplemented with L-glutamine, penicillin/streptomycin, 
and 10% FBS (Lonza). Tumor specimens were collected 
at the onset of disease from 120 patients, who were 
diagnosed with a primary NB between 2002 and 2008, and 
referred to the Gaslini Children’s Hospital (Genoa, Italy). 
All analyses involving human specimens were performed 
according to the Helsinki declaration. Tumor samples 
included only specimens with a neuroblastic cell content 
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>70%. Biologic information of the 22 NB tumor samples 
selected for miRNA genome-wide screening are listed in 
Supplementary Table 2.
RNA and miRNA extraction
Total RNA containing miRNAs was extracted by 
miRNeasy Mini kit (Qiagen), including a DNase step, 
according to the manufacturer’s instructions. The integrity 
of total RNA and miRNAs was checked by RNA 6000 
Nano and Small RNA assays, respectively, on the 2100 
Bioanalyzer (Agilent Technologies) and quantification 
performed by Nanodrop ND-1000 spectrophotometer 
(Thermo Scientific). Only RNAs with a RIN ≥7 were 
included in subsequent experiments. One μg of total 
RNA, containing miRNAs, was retro-transcribed using 
miScript Reverse Transcription Kit (Qiagen) and miScript 
HiFlex Buffer in a final volume of 20 μl. A poly(A) tag 
was added during the reaction and reverse transcription 
(RT) was performed in presence of both oligo-dT and 
random primers. The oligo-dT primers had a universal tag 
sequence on the 5' end that, with a specific miScript primer 
(Qiagen) different for each miRNA, allowed amplification 
in the qPCR step.
ALK qPCR
Expression of ALK mRNA was analyzed in both 
NB cell lines and samples by using 25 ng of cDNA in 
two independent experiments, in duplicate, on EpGradient 
Realplex PCR System (Eppendorf), using RealMasterMix 
(Eppendorf). We used specific 6FAM labeled TaqMan 
Assays (Applied Biosystems) for ALK, and employed the 
geNORM Kit (Primerdesign) to choose the best reference 
genes (18S, GAPDH and UBC). The comparative ΔCt 
method was then applied, normalizing ALK threshold cycle 
values on the geometric mean of the three housekeeping 
genes. All qPCR analyses were conducted in accordance 
to the MIQE guidelines for qPCR research reporting [68], 
as detailed in Supplementary Table 4.
Genome-wide miRNA expression profiling
We performed miRNA expression profiling starting 
from 100 ng of total RNA. MiRNAs were labeled 
according to Microarray System protocol v.2.4 (Agilent 
Technologies). Briefly, Labeling Spike-In were added 
to 100 ng of total RNA and then dephosphorylated and 
labeled using microRNA Complete Labeling and Hyb 
Kit. Samples were then purified using Micro Bio-Spin 6 
(Bio-Rad). After adding Hyb Spike-In, each sample was 
hybridized at 55°C for 20 hours on Human microRNA 
Microarray G4471A-029297 (Agilent Technologies), 
containing probes for 866 human miRNAs. After 
washing, slides were scanned by Agilent G2565CA 
scanner and images processed by Feature Extraction (FE) 
software using Agilent HD_miRNA protocol (Agilent 
Technologies). Raw and normalized data were deposited 
at National Center for Biotechnology Information Gene 
Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/
geo/) and are accessible through GEO accession number 
GSE86889, containing GSE84841 and GSE86652 that 
refer to NB cell lines and NB samples, respectively.
Statistical analysis of miRNA expression
Tab-delimited text files containing FE results were 
acquired and analyzed in R v3.1.3 software environment 
(www.r-project.org) using the limma package [69] of 
Bioconductor (www.bioconductor.org). NB cell lines 
analysis included 16 text files corresponding to the 
two groups identified on the basis of the different ALK 
expression. ALK+ subgroup included the following cell 
lines: GILIN, KELLY, IMR5, IMR32, LAN1, LAN5, 
UKF-NB3, SH-SY5Y, SKNBE2, SKNSH, whereas ALK- 
subgroup included the following: ACN, GICAN, GIMEN, 
LA1-5S, SKNAS, SKNBE2C. Tumor samples analysis 
included 22 text files corresponding to the two groups 
identified on the basis of the different ALK expression. 
ALK+ group comprised the following samples: 2716, 
2841, 2968, 2653, 2230, 2240, 2854, 2200, 2271, 2368, 
2212, whereas ALK- group comprised the following 
samples: 2996, 2916, 2624, 2616, 2265, 2731, 2347, 
2221, 2503, 2674, 2243. From such tab-delimited text 
files, only probes whose name starts with 'hsa' (FE field 
name ProbeName) were considered for further analysis 
(14192 features). To perform a quantitative analysis, 
only spots that satisfied the quality constraints showed 
in Supplementary Table 3 were used in the subsequent 
analysis as ‘detected’ spot. Background was subtracted 
from signal for each detected spot (we used the value 
with FE field name gBGSubSignal). Probes with less 
than 5 of detected spots across all arrays in one of the 
two groups (ALK+ and ALK-) were removed from the 
analysis. In NB cell lines 11701 probes were removed and 
2491 were kept for further analysis, whereas in NB tumor 
samples 6992 probes were removed and 7200 were kept. 
Samples with a number of detected spots smaller than the 
MEAN-2SD of all the spots distribution across arrays 
were removed (SKNBE2 cell line and samples 2731 and 
2347 were removed). Background corrected intensities of 
duplicate spots on each array were averaged (total number 
of averaged probes was 388 in NB cell lines and 675 in 
tumor samples). Data were then log2-transformed and 
normalized for between-array comparison using quantile 
normalization [70] and scale normalization [71, 72] for 
NB cell lines and tumor samples, respectively. Differential 
expression analysis between ALK+ and ALK- categories 
was carried out using Student's t-test (unpaired, two-tailed, 
unequal variance). MiRNAs with raw p-values < 0.05 were 
selected: 71 miRNAs in NB cell lines and 43 miRNAs in 
tumor samples. We used hierarchical clustering to detect 
similarity relationships in microRNA log2-transformed 
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expressions. Agglomerative hierarchical clusters were 
computed using the Euclidean distance between single 
vectors and the Ward method [73].
MiRNA qPCR
We carried out qPCR to validate microarray results. 
cDNA was retro-transcribed from NB cell lines and tumor 
samples and amplified with a miRNA-specific miScript 
Primer Assay and the miScript SYBR Green PCR Kit 
(Qiagen), containing the miScript Universal Primer and 
QuantiTect SYBR Green PCR Master Mix, in a final 
volume of 20 μl. The miRNA mature-specific miScript 
Primers were specific for the following miRNAs: let-
7g-5p, let7i-5p, miR-21-5p, miR-22-3p, miR-23a-3p, 
miR-29a-3p, miR-29b-3p, miR-29b-1-5p, miR-100-5p, 
miR-221-3p, miR-424-5p, miR-451a, miR-503-5p, miR-
520e and miR-526b-3p. For miScript PCR Controls we 
used SNORD95 snoRNA and the RNU6 snRNA. The 
comparative ΔCt method was then applied.
Cloning of ALK 3’-UTR
To generate the pMIR-ALK-UTR vector, the full-
length wild type sequence of ALK-3’-UTR was amplified 
by PCR from genomic DNA of UKF-NB3 cell line. 
Forward primer (5’-AATTACTAGTgctcggtcgcacactcact
tc-3’) was designed with a SpeI restriction site and reverse 
primer (5’-AATTAAGCTTTTagtcattacaaataactcc-3’) with 
a HindIII restriction site. Both restriction enzymes SpeI 
and HindIII were from New England Biolabs. ALK 3’-
UTR was then cloned into the 3’-UTR polylinker site of 
the Firefly luciferase expressing vector pMIR-REPORT™ 
Luciferase (Life Technologies). Sanger sequencing was 
performed on the pMIR-REPORT-ALK-3’-UTR vector to 
verify that no mutation was introduced.
Dual luciferase assay
Luciferase assay was carried out in SKNAS cell 
line that showed no endogenous expression of ALK. 
Cells were seeded in 96-Well Optical-Bottom Plates 
with Polymer Base suitable for luminometer assay 
(Thermo Scientific). Transient transfections of either 
the pMIR-REPORT-ALK-3’-UTR or the empty pMIR-
REPORT along with a pGL4.75 vector containing the 
renilla luciferase, employed for normalization of results, 
were performed 24 hours after cell seeding. Cells were 
co-transfected with miR-424-5p or miR-503-5p double 
stranded synthetic miRNA mimics (Qiagen) using 
Attractene transfection reagent (Qiagen), according 
to the manufacturer’s protocol. Cells transfected 
with AllStars Negative Control siRNA (Qiagen) and 
untransfected cells were used as negative controls. 
Firefly and renilla luciferase activities were assessed 
48 and 72 hours post transfection using the Dual 
Luciferase Reporter Assay System (Promega). For 
the luciferase assay, 20 μl of PLB buffer 1X (Passive 
Lysis Buffer, Promega) were added to each well and 
plates incubated for 15 minutes at room temperature 
on a thermomixer with the shaker on. Then, 20 μl of 
Firefly luciferase substrate (Luciferase Assay Reagent, 
LARII, Promega) were added to each well and light 
units measured by the plate reader Centro XS3 LB 960 
Microplate Luminometer (Berthold Technologies). After 
firefly luciferase reading, 20 μl of the renilla luciferase 
substrate (Stop&Glow buffer, Promega) were added and 
light intensities measured. Each miRNA transfection 
was performed in 6 to 12 replicates and repeated in 
three independent experiments. Firefly luciferase 
was normalized to renilla luciferase activity, and then 
normalized to the luciferase activity ratio observed in 
the empty vector. Negative Control siRNA values were 
set as 100%.
miRNA mimics transfection
SKNSH, NB1 and SKNAS cell lines, showing 
either detectable or high levels of ALK expression, or 
no ALK expression, respectively, were transfected with 
miR-424-5p and miR-503-5p mimics (Qiagen), in parallel 
with a negative control (AllStars Negative Control 
siRNA, Qiagen), using HiPerFect transfection reagent 
(Qiagen), according to the manufacturer’s protocol. 
Transfections were performed in T25 flasks with 1.5x106 
cells. Complexes composed by miRNA mimics and 
HiPerFect reagent were separately prepared, incubated at 
room temperature for 15 minutes and added directly to 
cell medium after cell seeding at a final concentration of 
20 nM.
Western blotting
A standard western blot protocol was carried out to 
evaluate ALK protein expression in cell lysates of NB cell 
lines. After 48 and 72 hours from transfection, cells were 
washed twice with ice-cold PBS and lysed with 50-100 μl 
of lysis buffer (Invitrogen), supplemented with a cocktail 
of protease inhibitors and PMSF (phenylmethylsulfonyl 
fluoride) (Sigma-Aldrich). Lysates were vortexed every 
10 minutes and incubated on ice, for a total of 30 minutes, 
and then cleared by spinning. Proteins were separated in 
Mini-PROTEAN® TGX™ Precast 4-20% Gels (Biorad), 
and transfer was performed by Trans-Blot Turbo transfer 
system (Biorad). Membranes were incubated with primary 
antibodies for ALK (Cell Signaling) and GAPDH (Cell 
Signaling), which was used as a control for equal protein 
loading. Goat anti-rabbit IgG HRP conjugated secondary 
antibody was from Santa Cruz Biotechnologies. Blots 
were developed with Amersham’s ECL Prime (GE 
Healthcare) and images acquired by a chemiluminescent 
detection system (Uvitec Cambridge). Quantification of 
western blot bands was performed by ImageJ [74].
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MTT assay
Cells were seeded at a concentration ranging from 
1x104 to 1.5x104 per well in six replicates, transfected in 
96-well plates and additioned with 20 μl of 5 mg/l MTT 
at 48 and 72 hours post-transfection and incubated for 4 
hours. Then, 200 μl of DMSO were added to each well and 
absorbance was read at 595 nm and background at 655 nm. 
Background values were then subtracted from MTT readings 
and each sample was compared to the negative control.
Cell cycle analysis
Human NB cell lines (106) were harvested 48 hours 
after transfection, washed twice with cold PBS, fixed 
in 70% ethyl alcohol and kept at 4°C. Cells were then 
washed twice in cold PBS and incubated 30 minutes at 
room temperature, in the dark, in a PBS based solution 
containing 0.05 mg/ml propidium iodide, 0.05% Triton 
X100 and 0.2 mg/ml RNAse A. After incubation, cells 
were washed in PBS and prepared for the cytometric 
analysis. Cell cycles were run on a FACScan and DNA 
content was analyzed using ModeFIT.
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